Corticoids in Severe Community-Acquired Pneumonia (CAP)

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy of glucocorticoids as an adjuvant therapy in patients with severe community-acquired pneumonia (CAP) (Fine V). The hypothesis of the study is that glucocorticoids can modulate the excessive inflammatory response in patients with severe CAP without any significant side effects, showing a benefit in the percentage of non-response to the empiric antimicrobial treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Clinic of Barcelona
• Treatments: Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Severe community-acquired pneumonia Fine V

• CRP >=15 mg/100 mL

Exclusion Criteria:

• Major contraindications for corticosteroids, such as uncontrolled diabetes, immunosuppression

• Previous glucocorticoid treatment during the previous month

• Documented extrapulmonary infection

• Previous hospitalization in the previous month